Cargando…

Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation

Immune checkpoint inhibitors have gained an established role in the treatment of different tumors. Indeed, their use has dramatically changed the landscape of cancer care, especially for tumor types traditionally known to have poor outcomes. However, stimulating anticancer immune responses may also...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bardoscia, Lilia, Pasinetti, Nadia, Triggiani, Luca, Cozzi, Salvatore, Sardaro, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591245/ https://www.ncbi.nlm.nih.gov/pubmed/34790123 http://dx.doi.org/10.3389/fphar.2021.746853

Ejemplares similares

Sixteen-Year Follow-Up in a Cavernous Sinus Hemangiopericytoma: Improved Outcomes over Radiotherapy Advances
por: Detti, Beatrice, et al.
Publicado: (2022)

Immune-related adverse events of biological immunotherapies used in COVID-19
por: Baracaldo-Santamaría, Daniela, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) for Oligorecurrent/Oligoprogressive Mediastinal and Hilar Lymph Node Metastasis: A Systematic Review
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Epithelioid Hemangioendothelioma: An Overview and Update on a Rare Vascular Tumor
por: Sardaro, Angela, et al.
Publicado: (2014)

Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study
por: Colosini, Antonella, et al.
Publicado: (2022)

Adenoid Cystic Carcinoma/Basal Cell Carcinoma of the Prostate: Overview and Update on Rare Prostate Cancer Subtypes
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Pulmonary epithelioid hemangioendothelioma presenting with vertebral metastases: a case report
por: Sardaro, Angela, et al.
Publicado: (2014)

State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis
por: Najafi, Masoumeh, et al.
Publicado: (2022)

Current landscape and tailored management of immune-related adverse events
por: Liu, Wenhui, et al.
Publicado: (2023)

Common Immune-Related Adverse Events of Immune Checkpoint Inhibitors in the Gastrointestinal System: A Study Based on the US Food and Drug Administration Adverse Event Reporting System
por: Bai, Xiaoyin, et al.
Publicado: (2021)

Impact of the COVID-19 Pandemic on Radiotherapy Supply
por: Tramacere, Francesco, et al.
Publicado: (2021)

Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature
por: Cozzi, Salvatore, et al.
Publicado: (2022)

Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals
por: Sardaro, Angela, et al.
Publicado: (2022)

Radiation-induced breast angiosarcoma: report of two patients after accelerated partial breast irradiation (APBI) and review of the literature
por: Cozzi, Salvatore, et al.
Publicado: (2021)

Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
por: Gao, Ling, et al.
Publicado: (2019)

Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Pancreatic Adverse Events Associated With Immune Checkpoint Inhibitors: A Large-Scale Pharmacovigilance Analysis
por: Zhang, Yue, et al.
Publicado: (2022)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
por: Kumar, Vivek, et al.
Publicado: (2017)

Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS)
por: Su, Si, et al.
Publicado: (2023)

The Role of Multiparametric Magnetic Resonance in Volumetric Modulated Arc Radiation Therapy Planning for Prostate Cancer Recurrence After Radical Prostatectomy: A Pilot Study
por: Sardaro, Angela, et al.
Publicado: (2021)

Management and prediction of immune-related adverse events for PD1/PDL-1 immunotherapy in colorectal cancer
por: Sun, Liting, et al.
Publicado: (2023)

Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation
por: Bardoscia, Lilia, et al.
Publicado: (2022)

Evaluation of the Direct Costs of Managing Adverse Drug Events in all Ages and of Avoidable Adverse Drug Events in Older Adults in Japan
por: Katsuno, Hayato, et al.
Publicado: (2021)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System
por: Guo, Haoning, et al.
Publicado: (2022)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
por: Ma, Pan, et al.
Publicado: (2022)

Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system
por: Guo, Qiang, et al.
Publicado: (2022)

Adverse events associated with molnupiravir: a real-world disproportionality analysis in food and drug administration adverse event reporting system
por: Liang, Yankun, et al.
Publicado: (2023)

Corrigendum: Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system
por: Guo, Haoning, et al.
Publicado: (2022)

Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting
por: de Camargo, Mayara Costa, et al.
Publicado: (2019)

Variation in adverse drug events of opioids in the United States
por: Liu, Edward Y., et al.
Publicado: (2023)

Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system
por: Jiao, Xue-Feng, et al.
Publicado: (2023)

Chemical crosslinkers enhance detection of receptor interactomes
por: Corgiat, Brian A., et al.
Publicado: (2014)

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy
por: He, Xiujing, et al.
Publicado: (2021)

Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system
por: Wang, Feifei, et al.
Publicado: (2022)

Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study
por: Les, Iñigo, et al.
Publicado: (2022)

Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies
por: Lee, Shu-Ping, et al.
Publicado: (2019)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
por: Ma, Zhuo, et al.
Publicado: (2021)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_49hr2h9t0rqsbcq95s8bdqqlf1